**MOLECULAR AND CLINICAL ONCOLOGY 6: 197-200, 2017**

**Abstract.** Peripheral primitive neuroectodermal tumors (pPNETs) are a group of aggressive neoplasms that are most commonly encountered in pediatric patients and may be located in the abdomen, pelvis, thoracopulmonary region and, rarely, in the head and neck region. pPNETs in adults are extremely rare. The present study reports a case of pPNET located in the hip muscles with bone metastasis. The patient was a 44-year-old woman who complained of progressive pain and swelling with a mass near the left hip. Computed tomography (CT) and enhanced CT revealed a soft tissue mass lesion in the hip muscle group measuring 4.3x4.3x4.4 cm. The lesion was ill-defined, heterogeneous, exhibiting mild post-contrast enhancement. There was a large number of bent neovessels and several branches from the left internal iliac artery and deep femoral artery on enhanced CT scan. Triple-phase dynamic imaging with integrin \(\alpha_v\beta_3\)-targeted \(^{99m}\)Tc-3P-RGD\(_2\) as the radiotracer revealed increased blood perfusion and radiotracer aggregation in the large, ill-defined, heterogeneous, hypodense mass and adjacent bone. The patient was suspected of having pPNET with bone metastasis, which was confirmed by histological examination of a sample obtained by needle aspiration. Due to the high blood perfusion of primary pPNETs and high RGD uptake by the primary and metastatic lesions, chemembolization and anti-angiogenic therapy were considered to be the optimal therapeutic choice. This also suggested that \(^{177}\)Lu-labeled RGD has great potential for the targeted treatment of pPNETs with multiple metastases.

**Introduction**

Primitive neuroectodermal tumors (PNETs) are a rare group of malignant tumors of neuroectodermal origin. PNETs are most commonly encountered in pediatric patients with diverse clinical manifestations, and are classified into three groups based on the tissue of origin: Central nervous system (CNS) PNETs, neuroblastoma and peripheral PNETs (pPNETs) derived from tissues outside the CNS and autonomic nervous system (1). pPNETs occur predominantly during infancy or childhood, and are located in the abdomen (2,3), thoracopulmonary region (4,5) and, rarely, in the head and neck region (6). pPNETs are extremely rare in adults, particularly in the hip muscles with bone metastasis. Metastasis is considered to be the most significant prognostic factor, and patients without metastasis may have a relatively better prognosis and longer survival time. Early correct diagnosis and accurate staging are crucial for selecting the optimal therapeutic regimens (7).

**Case report**

A 44-year-old woman was referred to our hospital on April 8th, 2015, with a 1-year history of progressive pain, swelling and a mass near the left hip, which had worsened over the previous month. The patient had no history of trauma, surgery, bone fracture, or accident. There was no other significant family or past medical history. Physical examination revealed a solid soft mass near the upper 1/4 of the left thigh, ~8 cm in diameter. Increased skin temperature and limited hip mobility were also observed. Tumor markers, including carcinoembryonic antigen, thyroglobulin, neuron-specific enolase, cytokeratin 19 fragment and cancer antigen 19-9 were all within the normal range. A plain CT scan of the pelvis and upper thigh was performed, which revealed a soft tissue mass lesion in the hip muscles measuring 4.3x4.3x4.4 cm (Fig. 2A). The lesion was an ill-defined, aggressive, heterogeneous, hypodense mass with multiple internal lower-density areas and mild post-contrast enhancement (Fig. 2B and C). There was a large number of bent neovessels and several branches from the left internal iliac artery and deep femoral artery on enhanced CT angiography (Fig. 2D). Three-phase dynamic imaging was
performed immediately after the injection of $^{99m}$Tc-3P-RGD$_2$ via the right ulnar vein. Blood perfusion (Fig. 1A, posterior view) and blood pooling (Fig. 1B, posterior view) images revealed increased blood perfusion and blood pooling in the soft mass. Delayed planar (Fig. 1C, anterior and posterior view) and single-photon emission (SPECT)-CT images acquired at 1 h showed a non-uniformly increased uptake of integrin $\alpha_v\beta_3$-targeting $^{99m}$Tc-3P-RGD$_2$ with a central decreased core (Fig. 1D). The soft mass was localized at the posteromedial muscle group of the left hip and presented as a large (5.3x2.7x3.1 cm), ill-defined, aggressive, heterogeneous, hypodense mass with multiple internal lower-density areas. Regional accumulation of $^{99m}$Tc-3P-RGD$_2$ may be seen in the ischium and ilium near the left hip joint, without significant bone density changes on computed tomography. The suspected diagnosis was soft tissue sarcoma or pPNET with bone metastasis.
observed in the ischium and ilium near the left hip joint and the suspected diagnosis was soft tissue sarcoma or pPNET with bone metastasis.

Histopathological examination of the biopsy sample (hematoxylin and eosin staining) revealed a highly cellular tumor composed of a diffuse, compact sheet of tumor cells displaying monomorphous, small round, finely vesicular nuclei and occasional necrosis (Fig. 2E). The immunohistochemical (IHC) staining for CD99 and FLI1 demonstrated positive (+++) and moderately positive (+) results, respectively (Fig. 2F). Chemoembolization and anti-angiogenic treatment were performed via the left internal iliac artery and left deep femoral artery, respectively.

Discussion

From a pathological perspective, pPNETs and Ewing sarcomas (ESs) are both composed of small round cells with identical histopathological, IHC and molecular characteristics. They are currently classified into the same tumor family with identical chromosomal translocations, and they generally represent different manifestations of the same tumor with similar genetic alterations. ES occurs predominately in the bone, while pPNETs are more common in soft tissues, such as the kidney (2,6), masseter muscle (3) and lungs (5). Furthermore, pPNETs mainly occur in children. We herein report a case of pPNET in an adult patient, originating in the hip muscles with bone metastasis. Unambiguous differentiation of pPNETs from other small round cell tumors, such as CNS PNETs, poorly differentiated carcinoma, lymphoma, desmoplasmic small round cell tumor and rhabdomyosarcoma, is difficult but of vital significance. These tumors may be difficult to diagnose due to their primitive morphology. Cell membranous immunoeexpression of CD99 (F) and FLI1 (G) are highly reliable markers for the definitive diagnosis of pPNET (8-10).

Tumor site, volume and the presence of metastasis, are significant prognostic factors for pPNETs. Radiology may offer important information for the diagnosis and prognosis of pPNETs. As in the present case, pPNETs commonly present as large, ill-defined, aggressive, heterogeneous, hypodense masses, exhibiting heterogeneous enhancement with varying internal lower-density regions (11,12). Due to the high incidence of metastasis at presentation, a full metastatic workup is warranted in cases with suspected pPNET. Furthermore, as pPNET is mainly diagnosed via pathological examination of biopsy samples or surgical specimens, more extensive investigations, such as nuclear medicine imaging, including whole-body technetium 99m bone scan or positron emission tomography imaging, are indicated (13). 

best of our knowledge, the first report of triple-phase $^{99m}$Tc-3P-RGD$_2$ imaging (plain and SPECT-CT) for the diagnosis and staging of a patient with pPNET. The blood perfusion results of the lesion were consistent with that from enhanced CT. In addition to the CT data, $^{99m}$Tc-3P-RGD$_2$ SPECT-CT imaging also demonstrated bone metastasis, which was negative on CT in this case. The regional aggressive nature and metastatic lesions precluded complete surgical excision. Triple-phase $^{99m}$Tc-3P-RGD$_2$ imaging supported the use of transarterial chemoembolization and anti-angiogenic treatment (20). With the development of therapeutic radionuclide labeling RGD, such as $^{17}$Lu-RGD$_4$, integrin $\alpha_v\beta_3$-targeted radiotherapy appears to be promising for the future treatment of pPNETs with bone metastasis (21).

References


